OAM
INSY

Origin Asset Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Origin Asset Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-8,162
Closed -$234K – 153
2015
Q4 		$234K Buy
+8,162
New +$226K 0.02% 133

Other funds holding INSY

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Origin Asset Management's INSY Position: Q1 2016 in Review

Origin Asset Management sold out of Insys Therapeutics, Inc. (INSY) in Q1 2016, closing a stake of 8,162 shares — an estimated $234K sold.

Origin Asset Management first reported a position in INSY in Q4 2015 and held it in 1 quarter. The position peaked at $234K in Q4 2015. 138 funds tracked by Wall St. Rank hold INSY as of Q1 2016.

  • Origin Asset Management reported no remaining Insys Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Origin Asset Management sold 8,162 Insys Therapeutics, Inc. shares in Q1 2016, an estimated $234K.
  • Origin Asset Management first reported a position in Insys Therapeutics, Inc. in Q4 2015 and held it in 1 quarter.
  • Origin Asset Management's Insys Therapeutics, Inc. position peaked at $234K in Q4 2015.
  • 138 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2016.

Based on Origin Asset Management's 13F filing for Q1 2016, filed 2 Jun 2016.